This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Prospective Observational Study to Evaluate the Quality of Life and the Costs in a Real Life Setting in Patients Who Are Treated With 90Y-Zevalin

This study has been completed.
Information provided by:
Bayer Identifier:
First received: July 16, 2010
Last updated: August 23, 2010
Last verified: August 2010
The objective of this study is to compare hematological toxicity, costs, health-related quality of Life (HR-QOL) and outcomes observed in real life in the Belgian Non-Hodgkin Lymphoma (NHL) population receiving 90Y-Zevalin, with model-predicted data at reimbursement on the basis of a clinical trial in heavily pre-treated NHL.

Condition Intervention
Lymphoma, Follicular Non-Hodgkin Lymphoma Drug: [90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Prospective Observational Study to Evaluate Quality of Life and Costs in a Real Life Setting in Patients Treated With 90Y-Zevalin

Resource links provided by NLM:

Further study details as provided by Bayer:

Primary Outcome Measures:
  • The medical resources consumed due to hematological adverse events that occurred following treatment with 90Y-Zevalin treatment [ Time Frame: one year after inclusion ]

Secondary Outcome Measures:
  • the health related quality of life prior to and following treatment (using EQ-5D and FACT-LYM) [ Time Frame: baseline: before 1st administration, 8 days after baseline, 1, 2 & 3 months after baseline ]
  • the clinical outcomes (survival status, response status), TTNT (time to next treatment) [ Time Frame: 1 year ]

Enrollment: 30
Study Start Date: August 2007
Study Completion Date: May 2009
Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Group 1 Drug: [90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)
Zevalin was administered according to the directives in the approved package leaflet.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All patients with relapsed or refractory FL who have been treated with 90Y-Zevalin in Belgium within the first 24 months after ethics approval

Inclusion Criteria:

  • Advanced cancer of the lymph nodes of follicular type at study inclusion
  • The patient has relapsed or has refractory disease, after previous treatment with rituximab
  • Treating physician has decided to treat the patient with a 90Y-Zevalin regimen
  • The patient is >= 18 years of age
  • Patient has given informed consent

Exclusion Criteria:

  • Patient is unwilling or unable to give informed consent
  • Patient is participating in another clinical trial
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01164696

Many Locations, Belgium
Sponsors and Collaborators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
Responsible Party: Medical Director, Bayer Schering Pharma AG Identifier: NCT01164696     History of Changes
Other Study ID Numbers: 13455
Study First Received: July 16, 2010
Last Updated: August 23, 2010

Keywords provided by Bayer:
Quality of Life, Health Care Costs

Additional relevant MeSH terms:
Lymphoma, Non-Hodgkin
Lymphoma, Follicular
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs processed this record on July 26, 2017